We are live on ! Find out more
PGNX

Progenics Pharmaceuticals Inc
PGNX

Delisted

PGNX was delisted on the 19th of June, 2020.

Back to rankings

149 hedge funds and large institutions have $491M invested in Progenics Pharmaceuticals Inc in 2018 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 64 increasing their positions, 32 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 32

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

4% less funds holding

Funds holding: 155 → 149 (-6)

6% less capital invested

Capital invested by funds: $522M → $491M (-$31.1M)

17% less call options, than puts

Call options by funds: $7.33M | Put options by funds: $8.83M

19% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 26

Holders
149
Holders Change
-6
Holders Change %
-3.87%
% of All Funds
3.41%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
21
Increased
64
Reduced
32
Closed
26
Calls
$7.33M
Puts
$8.83M
Net Calls
-$1.51M
Net Calls Change
-$10.3M

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$27.8M
2
RCM
RA Capital Management
Massachusetts
+$23.3M
3
State Street
State Street
Massachusetts
+$18.3M
4
BlackRock
BlackRock
New York
+$14.6M
5
Citadel Advisors
Citadel Advisors
Florida
+$11.5M

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$7.87M
2
Federated Hermes
Federated Hermes
Pennsylvania
-$4.44M
3
Morgan Stanley
Morgan Stanley
New York
-$3.32M
4
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management
California
-$2.52M
5
PA
Pinnacle Associates
New York
-$1.99M
Name Holding Trade Value Shares
Change 		Change in
Stake
TI
151
Trexquant Investment
Connecticut
– -$281K -35,008 Closed
CCIA
152
Campbell & Co Investment Adviser
Maryland
– -$172K -21,410 Closed
EIM
153
Essex Investment Management
Massachusetts
– -$160K -19,851 Closed
FRM
154
Fox Run Management
Connecticut
– -$150K -18,678 Closed
OAM
155
Oberweis Asset Management
Illinois
– -$137K -17,100 Closed
CG
156
Clinton Group
New York
– -$121K -14,996 Closed
Teacher Retirement System of Texas
157
Teacher Retirement System of Texas
Texas
– -$115K -14,252 Closed
AWS
158
AJ Wealth Strategies
New York
– -$113K -14,004 Closed
ECM
159
Element Capital Management
New York
– -$104K -12,885 Closed
AB
160
Amalgamated Bank
New York
– -$97K -12,047 Closed
WMC
161
Westwood Management Corporation
Illinois
– -$96K -12,000 Closed
OPPM
162
Opus Point Partners Management
New York
– -$88K -10,891 Closed
PCM
163
Prelude Capital Management
New York
– -$78K -9,656 Closed
Envestnet Asset Management
164
Envestnet Asset Management
Illinois
– -$27K -3,296 Closed
CIBC Private Wealth Group
165
CIBC Private Wealth Group
Georgia
– -$22K -2,683 Closed
RE
166
RBC Europe
United Kingdom
– -$4.02K -500 Closed
CF
167
Centaurus Financial
California
– -$3K -330 Closed
WAS
168
Winch Advisory Services
Wisconsin
– -$2K -200 Closed
RCAG
169
Rehmann Capital Advisory Group
Michigan
– -$619 -77 Closed
CAG
170
Csenge Advisory Group
Florida
– +$169 +22 New
PFBT
171
Parkside Financial Bank & Trust
Missouri
– +$446 +58 New
SEI Investments
172
SEI Investments
Pennsylvania
– +$484 +63 New
VCM
173
Versant Capital Management
Arizona
– +$568 +74 New
3 4 5 6
7

PGNX Hedge Fund Activity: Q3 2018 in Review

149 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q3 2018, worth a combined $491M — down 6% from $522M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of PGNX and 21 opened new positions — a net loss of 5 holders — while 32 trimmed existing stakes and 64 added.

The largest buyer was Armistice Capital, adding an estimated $27.8M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $7.87M sold.

  • 149 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q3 2018, down from 155 in Q2 2018.
  • Funds reported $491M of Progenics Pharmaceuticals Inc stock for Q3 2018, down 6% quarter-over-quarter.
  • 21 funds opened new Progenics Pharmaceuticals Inc positions in Q3 2018 and 26 closed out, a net change of -5 holders.
  • The largest Progenics Pharmaceuticals Inc buyer in Q3 2018 was Armistice Capital, an estimated $27.8M added.
  • The largest Progenics Pharmaceuticals Inc seller in Q3 2018 was Baker Bros. Advisors, an estimated $7.87M sold.

Based on aggregated 13F filings for Q3 2018.